Neuromedicinos institutas - Company finances
|
EUR
|
2018
From: 2018-01-01
To: 2018-12-31
|
2019
From: 2019-01-01
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-02-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|---|
|
Financial data
|
||||||||
| Sales revenue | - | 286,217 | 374,448 | 600,106 | 583,740 | 660,749 | 779,000 | 869,662 |
| Profit before tax | - | - | - | - | -18,317 | 18,032 | 4,820 | 17,393 |
| Net profit | - | - | - | - | -18,317 | 17,131 | 4,097 | 14,312 |
| Equity | 22,670 | 48,713 | 57,855 | 80,911 | 62,594 | 79,724 | 83,821 | 98,133 |
| Liabilities | 59,491 | 76,573 | 0 | 134,684 | 202,683 | 217,350 | 253,830 | 359,769 |
| Non-current assets | 46,963 | 53,355 | 44,012 | 102,089 | 82,066 | 63,748 | 68,698 | 51,146 |
| Current assets | 38,516 | 77,812 | 94,831 | 115,824 | 183,211 | 233,326 | 268,953 | 406,756 |
| Total assets | 85,479 | 131,167 | 138,843 | 217,913 | 265,277 | 297,074 | 337,651 | 457,902 |
|
Taxes paid
|
||||||||
| STI taxes | - | - | - | - | - | 18,661 | 17,188 | 16,547 |
| Social insurance contributions | - | - | - | - | - | 15,326 | 10,310 | 4,602 |
|
Financial indicators
|
||||||||
| Revenue change y/y | - | - | +30.8% | +60.3% | -2.7% | +13.2% | +17.9% | +11.6% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | - | - | - | - | -6.9% | 5.8% | 1.2% | 3.1% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | - | - | - | - | -29.3% | 21.5% | 4.9% | 14.6% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | - | - | - | - | -3.1% | 2.6% | 0.5% | 1.6% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | - | - | - | - | -3.1% | 2.7% | 0.6% | 2.0% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | 2.6 | 1.6 | - | 1.7 | 3.2 | 2.7 | 3.0 | 3.7 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | - | 180,772 | 187,224 | 211,805 | 109,452 | 110,125 | 146,063 | 193,258 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Neuromedicinos institutas - Social security debts
| From | To | Debt, € |
|---|---|---|
| 2026-02-18 | 2026-03-01 | 0.30 |
| 2026-01-21 | 2026-01-29 | 0.30 |
| 2025-10-16 | 2025-10-30 | 73.08 |
| 2022-11-21 | 2022-11-27 | 0.16 |
| 2022-11-17 | 2022-11-18 | 0.16 |
| 2022-07-18 | 2022-07-20 | 87.46 |
| 2022-02-17 | 2022-02-21 | 0.81 |
| 2022-01-28 | 2022-01-30 | 0.81 |
| 2021-12-16 | 2021-12-19 | 897.98 |
Neuromedicinos institutas - VMI tax arrears
The company had no tax arrears (debts) to the State Tax Inspectorate
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Neuromedicinos institutas, VšI (company code 300109077) is a Public Institution operating in other education n.e.c. In 2025, revenue reached €869.7K, up 11.6% year on year and 31.6% over two years, confirming a steady expansion from €660.7K in 2023 and €779.0K in 2024. Net profit was €14.3K in 2025, compared with €4.1K in 2024 and €17.1K in 2023, while the profit margin improved from 0.5% to 1.6% after a weaker 2024. The balance sheet also expanded: total assets increased to €457.9K, equity to €98.1K, and liabilities to €359.8K. The equity ratio stood at 21.4%, and debt-to-equity was 3.67, indicating a liability-heavy capital structure. Return on equity was 14.6% and return on assets 3.1%, supported by an asset turnover of 1.90x. Revenue per employee was €217.4K and profit per employee €3.6K, suggesting relatively efficient turnover despite modest profitability.